Semaglutide for managing overweight and obesity (TA875)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 4 September 2023Published: 8 March 2023
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) (TA910)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2023
Liraglutide for managing overweight and obesity (TA664)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 December 2020
Naltrexone–bupropion for managing overweight and obesity (TA494)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 December 2017
Tirzepatide for managing overweight and obesity [ID6179]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 January 2025
Oral semaglutide for managing overweight and obesity [ID6188]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating obesity-related heart failure with preserved ejection fraction TS ID 11788Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC